On November 15, "Shijiazhuang Lianhua Qingwen Capsules sold out" appeared on Weibo hot searches.
A reporter from the Beijing Business Daily learned that after the release of the 20 Measures for Optimizing Epidemic Prevention and Control, many over-the-counter cold medicines, including Lianhua Qingwen Capsules, have become targets for hoarding by the public.
Lianhua Qingwen Capsules (Granules), as the world's first approved drug for the treatment of new coronary pneumonia, added the indication of "mild and common type of new coronavirus pneumonia" in April 2020.
As of the first half of 2022, the anti-cold products of the Lianhua Qingwen series have surpassed the cardiovascular and cerebrovascular products and become the largest business segment of Yiling Pharmaceutical.
Yiling Pharmaceutical responded that the production capacity is sufficient
According to hot search news, some pharmacies in Shijiazhuang Lianhua Qingwen are out of stock.
In addition, Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen, is headquartered in Shijiazhuang. The company has also experienced a phenomenon of full orders.
A reporter from Beijing Business Daily called a retail pharmacy in Shijiazhuang as a consumer. The staff of a pharmacy in Qiaoxi District, Shijiazhuang City said that in the past two days, consumers have been buying Lianhua Qingwen, and there are still some Lianhua Qingwen granules in the store. Lianhua Qingwen Capsules is out of stock.
A staff member of a pharmacy in Chang'an District, Shijiazhuang City said, "Lianhua Qingwen is sold out today, and the manager said that it may arrive tomorrow."
Regarding the out-of-stock of Lianhua Qingwen in Shijiazhuang pharmacy, the relevant person in charge of Yiling Pharmaceutical responded to the reporter of Beijing Business Daily that the company did not know the relevant situation, and the company's production was basically not affected, and the current sales situation was normal.
Regarding the production capacity issue, the other party stated that Yiling Pharmaceutical has been doing a series of work to increase production capacity in the past two years, and the current production capacity has been greatly improved.
The company's production plan is "production based on sales", and the production plan can be adjusted in time according to market demand to ensure market supply.
In response to the current panic buying of Lianhua Qingwen in the company, the relevant person in charge of Yiling Pharmaceutical said that the traditional self-collection of internal purchases in the company has been changed to online express delivery recently, and the time has been extended compared with self-collection.
Affected by the news that Lianhua Qingwen Capsule was "bought explosively", on November 15, Yiling Pharmaceutical rushed to the daily limit.
The trading market shows that on November 15, Yiling Pharmaceutical opened 4.86% higher, with an opening price of 36 yuan per share. Shortly after the opening, Yiling Pharmaceutical rushed to the daily limit. Yuan/share, an increase of 9.99%, with a total market value of 63.09 billion yuan, a turnover of 4.268 billion yuan on the day, and a turnover rate of 8.39%.
In addition to Yiling Pharmaceutical, the stock price of Yuyue Medical, whose main products include oxygen concentrators and ventilators, also rose sharply on November 15.
Lianhua Qingwen contributed nearly half of its revenue
The Lianhua Qingwen series has become the absolute trump card in Yiling Pharmaceutical's revenue.
At present, Yiling Pharmaceutical's products cover cardiovascular and cerebrovascular diseases, respiratory, diabetes and other clinical frequently-occurring and major diseases.
In the 2021 financial report, Yiling Pharmaceutical classified Lianhua Qingwen Capsules/Granules in the field of cold and respiratory.
Before 2020, cardiovascular and cerebrovascular products will be the core business of Yiling Pharmaceutical.
The 2019 financial report shows that Yiling Pharmaceutical achieved a revenue of 5.825 billion yuan, and its revenue of cardiovascular and cerebrovascular drugs and anti-cold drugs were 3.096 billion yuan and 1.703 billion yuan respectively. The profit contribution rates reached 53.36% and 58.14% respectively; the anti-cold drugs of Lianhua Qingwen contributed 29.35% and 30.59% to the company's revenue and profit respectively.
In April 2020, the State Drug Administration approved Lianhua Qingwen Capsules/Granules to add a new indication of "mild and common type of new coronavirus pneumonia" on the basis of the original approved indications.
In March 2022, in the newly released "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)", in addition to continuing to list Lianhua Qingwen Capsules (Granules) as the recommended drug for the medical observation period of traditional Chinese medicine treatment, it will also It is listed as a recommended drug for light and common types in the clinical treatment period (confirmed cases).
After the new indications were added, the revenue share of the business segment of the Lianhua Qingwen series has increased significantly.
In 2021, Yiling Pharmaceutical's total operating income will reach 10.117 billion yuan, a year-on-year increase of 15.19%; its net profit will be 1.344 billion yuan, a year-on-year increase of 10.27%.
Among them, the respiratory system products of the Lianhua Qingwen series accounted for 40.6% of the revenue, and the cardiovascular and cerebrovascular products accounted for 44.82% of the revenue that year.
By the first half of 2022, the anti-cold products of the Lianhua Qingwen series have surpassed the cardiovascular and cerebrovascular products and become the largest business segment of Yiling Pharmaceutical.
The sales of anti-cold products and cardiovascular and cerebrovascular products accounted for 45.87% and 40.85% respectively.
Buy medicines rationally and avoid excessive stockpiling
In March 2022, the Hebei Provincial Administration of Traditional Chinese Medicine organized relevant experts in the prevention and control of traditional Chinese medicine in the province to summarize the work experience in the prevention and control of traditional Chinese medicine in Hebei Province in the national "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)" TCM diagnosis and treatment plan On this basis, combined with the current epidemic situation and climate characteristics, the "Hebei Province New Coronavirus Pneumonia Prevention and Treatment Plan with Traditional Chinese Medicine (Trial Sixth Edition)" was formulated, which mentioned that for asymptomatic infections, the Chinese patent medicine Lianhua Qingwen Capsules is recommended (granules), Huoxiangzhengqi soft capsules (water, granules, dripping pills, etc.), Qingkailing soft capsules (granules), etc., choose according to your usual physical condition, and take according to the instructions.
Right now, not only Lianhua Qingwen, but also many over-the-counter cold medicines have become hoarded by the public.
A reporter from Beijing Business Daily learned from the relevant person in charge of Shineway Pharmaceuticals that Huoxiang Zhengqi products are also out of stock in many stores of the company's large pharmacy. They are out of stock in the morning and can be delivered in the afternoon.
"The company has listed the epidemic prevention and control drugs such as Shineway Huoxiang Zhengqi Soft Capsules as the primary production task, and is doing its best to produce and ensure supply."
A reporter from Beijing Business Daily called many pharmacies in Beijing and found that the current supply of medicines is normal.
According to the relevant person in charge of Dingdang Kuaiyao, the sales volume of Dingdang Kuaiyao related drugs has more than five times year-on-year.
Dingdang Kuaiyao has sufficient stocks of such drugs, and each store will replenish them at any time according to the sales situation, so as to fully guarantee the drug needs of the public.
At the same time, Dingdang Kuaiyao also recommends that users purchase medicines rationally and avoid excessive stockpiling of medicines.
Beijing Business Daily reporter Yao Qian Ding Ning